Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (14686)	9/17/2000 9:07:33 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Cacaito, before you stick up for the FDA and their so-called standards, read this carefully and tell me whats wrong with this picture.>>>> Read this...just approved this friday>>>>>>>>>> >>>>>>>>"For serious illnesses where patients need access to new medications, the FDA allows accelerated approval based on data from ongoing studies." ". At present, there are no results from controlled trials evaluating the effect of Kaletra on the progression of HIV. Full approval is granted based on review of additional safety and efficacy data from Phase III clinical trials." The link>http://biz.yahoo.com/prnews/000915/il_abbott__2.html So in fact, the fDA is compassionate for HIV, sure looks to me like the FDA standards dropped quite a bit for this open label trial. DAMN IT, GIVE THE KIDS A OPEN LABEL STUDY. >All just IMO, standard disclaimers

To: Cacaito who wrote (14686)	9/17/2000 9:48:52 AM
From: Robert K.	Respond to of 17367

Thank you for the kind words Cacaito. I will talk about the private placement another time(if you remind me). I do not wish to cloud the issue of bpi approvability with financial matters at this time. And I DO respect you decision to be solely in it for the money. IMO thats your choice. However if you have no money to lose, or make, why dont you support bpi here and give the kids a fighting chance. A benefit is a benefit no matter how well defined. Support approval or easy open label access. A person in your postition should support no less. Please consider.